5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow Complicated Urinary Tract Infection: new trials by email Literature Review of Complicated Urinary Tract Infection trials Research Report on Complicated Urinary Tract Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) Ceftolozane/Tazobactam, Meropenem - Complicated Urinary Tract Infection, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 134 | 2018-04-26 | 2023-05-06 |
| Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Sulbactam-ETX2514, Placebo, Imipenem-cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Entasis Therapeutics | 80 | 2018-01-17 | 2020-01-22 |
| A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) levofloxacin, plazomicin, placebo - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Achaogen, Inc. | 145 | 2010-07-13 | 2018-08-22 |
| Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections CXA-101, Ceftazidime - Complicated Urinary Tract Infection | Phase 2 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 129 | 2009-06-30 | 2018-10-18 |
| Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections NXL104/ceftazidime, Imipenem/Cilastatin - Complicated Urinary Tract Infection | Phase 2 | Completed | Pfizer | 137 | 2008-11-01 | 2018-05-25 |
Pyelonephritis (3) · Urinary Tract Infections (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Nephritis (3) · Nephritis, Interstitial (3) · Pyelitis (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Infections (1)
Ceftazidime (2) · Cilastatin, Imipenem Drug Combination (2) · Levofloxacin (1) · Meropenem (1) · avibactam (1) · ceftolozane (1) · ceftolozane, tazobactam drug combination (1) · plazomicin (1)
Achaogen, Inc. (1) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Entasis Therapeutics (1) · Merck Sharp & Dohme LLC (1) · Pfizer (1)
United States (3) · Poland (2) · Bulgaria (1) · Germany (1) · Greece (1) · Hungary (1) · Jordan (1) · Lebanon (1) · Mexico (1) · Romania (1) · Russia (1) · South Africa (1) · Turkey (Türkiye) (1) · Ukraine (1)
Ahmad Haidar, MD (1) · Anibal Calmaggi, MD (1) · Carole A Sable, MD (1) · Florian Wagenlehner, MD (1) · Ryszard Gellert, MD (1)
PMID 23145859, PMID 31843995, PMID 36689671
2016 (1)